MERS-CoV – a global threat

Source: WHO, Van Kerkhove
Mapping emergence and spillover risk of pathogens with epidemic and pandemic potential

Draft maps - work in progress. Please contact Maria Van Kerkhove (vankerkhovem@who.int), Barbara Han (hanb@caryinstitute.org), David Pigott (pigottdm@uw.edu)

Pathogens included: Dengue, Chikungunya, Zika, Henipaviruses: Hendra and Nipah, Mpox, MERS-CoV, Plague, Ebola, Marburg;
Pathogens to include: HPAI, CoV SARS-CoV-2 and begacoronaviruses Lassa fever, Rift Valley Fever, and Crimean-Congo Haemorrhagic Fever
Global priorities and available tools for Middle East respiratory syndrome coronavirus (MERS-CoV)

Sophie von Dobschuetz, WHO
Hala Abou El Naja, WHO EMRO

Emma Gardner, FAO
Gounalan Pavade, WOAH

ONE HEALTH QUADRIPARTITE COLLABORATION
MERS-CoV – a global threat

MERS-CoV is a WHO priority blueprint disease for R&D.

Reservoir host: dromedary camels

Sporadic spillover to humans

Human-to-human transmission in healthcare settings or communities

Source: WHO, Van Kerkhove
International regulations for the notification of MERS-CoV

For human cases: WHO IHR

For animal cases: WOAH WAHIS
Timeline of MERS-CoV human cases

WHO MERS-CoV global epidemic curve

Significant changes in management and follow up of cases/ clusters; improvements in infection prevention and control; reductions in secondary transmission

COVID-19 pandemic

Other countries: AUSTRIA, Algeria, BAHRAIN, CHINA, EGYPT, FRANCE, GERMANY, GREECE, IRAN, ITALY, JORDAN, KUWAIT, LEBANON, MALAYSIA, NETHERLANDS, OMAN, PHILIPPINES, QATAR, THAILAND, TUNISIA, TURKEY, UNITED ARAB EMIRATES, UNITED KINGDOM, USA, YEMEN

Please note that the underlying data is subject to change as the investigations around cases are ongoing. Onset date estimated if not available.
MERS-CoV field studies conducted in camels

Phylogenetic differences in MERS-CoV detected globally:

**Arabian Peninsula:**
- Clade A (extinct)
- Clade B

**Africa:**
- Clade C

Source: FAO
Risk of MERS-CoV emergence and spillover

WHO / IHME MERS-CoV risk map for MERS-CoV spillover

Draft maps - work in progress. Please contact Maria Van Kerkhove (vankerkhovem@who.int), Barbara Han (hanb@caryinstitute.org), David Pigott (pigottdm@uw.edu)
### Geographical and temporal surveillance gaps

**Countries with field studies in camels, over the camel population density**

![Map of countries with field studies in camels](image)

**Countries at risk of MERS-CoV without studies in humans or animals**

![Map of countries at risk without studies](image)

<table>
<thead>
<tr>
<th>Region/Country</th>
<th>Year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa - Camelus dromedarius only</td>
<td>3</td>
<td>20</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burkina Faso</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Egypt</td>
<td></td>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethiopia</td>
<td></td>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kenya</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Middle East</td>
<td>20</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jordan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oman</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Qatar</td>
<td>20</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>United Arab Emirates</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Legend**
- camel surveillance ongoing
- confirmed human case reported

**Need for representative surveillance data and sequences**
Increasing sequencing capacities worldwide

**Number of Member States that have SARS-CoV-2 sequencing capability**

- **Dec 2022**: 163 of 194
- **Jul 2022**: 143 of 194
- **Jan 2022**: 131 of 194
- **Oct 2021**: 115 of 194
- **May 2021**: 105 of 194
- **Feb 2021**: 103 of 194

Source: WHO genomic sequencing strategy

**Global SARS-CoV-2 sequencing capacity**
Data as of 3 March 2021

**Maintaining and sustaining capacities**
**Utilizing capacities for other pathogens, like MERS-CoV**
**Building bioinformatic capacities**
Available tools – surveillance in humans and camels

1. WHO surveillance protocols/interim guidance updated:
   - Based on lessons learned from COVID-19
   - Make look-and-feel similar to existing UNITY protocols

2. FAO camel sampling guidance
   - To ensure good quality samples
   - For optimized MERS-CoV detection, isolation and genetic characterization

3. Quadripartite collaboration:
   - Study protocols for risk factor identification, generally and at the animal-human interface
   - Anthropological questionnaires
Available tools – WOAH Terrestrial Manual chapter on MERS-CoV

- Chapter 3.5.2. Middle East Respiratory Syndrome (Infection of dromedary camels with MERS-CoV) [https://www.woah.org/fileadmin/Home/eng/Health_standards/tahm/3.05.02_MERS-CoV.pdf]
- Provides test methods available for diagnosis of MERS and their purposes
- Updates on vaccines

<table>
<thead>
<tr>
<th>Method</th>
<th>Population freedom from infection</th>
<th>Individual animal freedom from infection prior to movement</th>
<th>Contribute to eradication policies</th>
<th>Confirmation of clinical cases</th>
<th>Prevalence of infection – surveillance</th>
<th>Immune status in individual animals or populations post-vaccination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Real-time RT-PCR</td>
<td>–</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>+++</td>
<td>–</td>
</tr>
<tr>
<td>Antigen detection</td>
<td>–</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Virus isolation and identification</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>+++</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

**Detection of the agent**

<table>
<thead>
<tr>
<th>Method</th>
<th>Detection of immune response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indirect IgG ELISAs</td>
<td>++</td>
</tr>
<tr>
<td>Pseudo-particle neutralisation assay</td>
<td>+</td>
</tr>
<tr>
<td>PRNT</td>
<td>+</td>
</tr>
<tr>
<td>VNT</td>
<td>+</td>
</tr>
</tbody>
</table>

**Detection of immune response**

**Key:** +++ = recommended for this purpose; ++ = recommended but has limitations; + = suitable in very limited circumstances; – = not appropriate for this purpose.

- RT-PCR = reverse-transcription polymerase chain reaction; IgG ELISA = immunoglobulin G enzyme-linked immunosorbent assay; PRNT = plaque reduction neutralisation test; VN = virus neutralisation.
MERS-CoV multicountry outbreak simulation exercise

Workshop at EMARIS, 14. March 2023, Muscat, Oman

Objectives:

• Identify the key stakeholders, roles and responsibilities within a multisectoral or One Health coordination mechanism

• Identify major steps to be adopted at country level for the preparedness, investigation of and response to zoonotic diseases under the One Health umbrella

• Learn from countries’ experiences about successes and challenges in implementing multi-sectoral prevention and control activities for zoonotic diseases like MERS

• Discuss the optimal multisectoral coordination and communication mechanisms

This will be turned into a fully-fledged regional simulation exercise (stay tuned)
Global collaboration on MERS

Tripartite workplan on MERS
- Field surveys in humans and animals
- Anthropological studies
- Knowledge, Attitudes and Practices (KAP) studies

Regular inter-agency coordination calls

Keeping the research agenda up to date

Global technical meetings:
- December 2017 – WHO HQ Geneva, Switzerland
- November 2021 – virtual
- **Planned for 27-29 November 2023** – Kingdom of Saudi Arabia
Global priorities for MERS-CoV

Outputs/recommendations from TPT MERS meeting

- Increase surveillance:
  - Humans and camels
  - Middle East and Africa
- Integrated surveillance for respiratory pathogens to include MERS-CoV
- One Health interventions to reduce zoonotic risk
- Feasibility and acceptability of camel vaccines
- Scientific and collaborative achievements from COVID pandemic leveraged
- OH data sharing mechanisms, tested in peace time

Source: Sam Bradd, Drawing Change
Thank you